Hepatitis C virus screening in community pharmacies: results on feasibility from a Swiss pilot

Abstract Background Hepatitis C virus (HCV) infections are a public health burden worldwide and often go undetected until sequelae develop. Offering HCV screening for the different vulnerable populations in community pharmacies could help prevent further undetected HCV infections. This pilot aimed t...

Full description

Bibliographic Details
Main Authors: Dominik Stämpfli, Tamara Leila Imfeld-Isenegger, Kurt E. Hersberger, Markus Messerli
Format: Article
Language:English
Published: BMC 2023-06-01
Series:BMC Infectious Diseases
Subjects:
Online Access:https://doi.org/10.1186/s12879-023-08362-1
_version_ 1797806871380230144
author Dominik Stämpfli
Tamara Leila Imfeld-Isenegger
Kurt E. Hersberger
Markus Messerli
author_facet Dominik Stämpfli
Tamara Leila Imfeld-Isenegger
Kurt E. Hersberger
Markus Messerli
author_sort Dominik Stämpfli
collection DOAJ
description Abstract Background Hepatitis C virus (HCV) infections are a public health burden worldwide and often go undetected until sequelae develop. Offering HCV screening for the different vulnerable populations in community pharmacies could help prevent further undetected HCV infections. This pilot aimed to assess the feasibility and pharmacist acceptance of HCV rapid antibody saliva testing in community pharmacies. Methods A structured pharmaceutical care intervention was developed that included addressing, informing, and screening clients, as well as referral and reporting to subsequent health care providers. Participating pharmacies from French-, German- and Italian-speaking parts of Switzerland were trained to provide this service to local vulnerable populations. Information on client recruitment, feasibility, and acceptability of HCV screening was collected. Results Of 36 pharmacies initially recruited, 25 started the pilot and approached 435 clients, 145 of whom (33%) were interested in screening. Eight of these rapid antibody tests returned positive (prevalence rate: 5.5%). Facilitators were being able to offer a free rapid test (73%), followed by having training prior to the project (67%) and having a new service to offer (67%). The possibility of clients reacting dismissively (53%) and of unsettling clients (47%) were reported to be the main barriers. Conclusions This pilot demonstrated the general feasibility of an HCV screening service with rapid antibody saliva testing in Swiss community pharmacies, which achieved a higher prevalence rate than national estimates. With appropriate communication training and remuneration, Swiss community pharmacies could be an important partner in implementing HCV elimination strategies.
first_indexed 2024-03-13T06:13:56Z
format Article
id doaj.art-ca2743412e5b4e7482c4e3bd56a0f889
institution Directory Open Access Journal
issn 1471-2334
language English
last_indexed 2024-03-13T06:13:56Z
publishDate 2023-06-01
publisher BMC
record_format Article
series BMC Infectious Diseases
spelling doaj.art-ca2743412e5b4e7482c4e3bd56a0f8892023-06-11T11:06:43ZengBMCBMC Infectious Diseases1471-23342023-06-0123111010.1186/s12879-023-08362-1Hepatitis C virus screening in community pharmacies: results on feasibility from a Swiss pilotDominik Stämpfli0Tamara Leila Imfeld-Isenegger1Kurt E. Hersberger2Markus Messerli3Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology, ETH ZurichHospital Pharmacy, Luzerner KantonsspitalPharmaceutical Care Research Group, Department of Pharmaceutical Sciences, University of BaselPharmaceutical Care Research Group, Department of Pharmaceutical Sciences, University of BaselAbstract Background Hepatitis C virus (HCV) infections are a public health burden worldwide and often go undetected until sequelae develop. Offering HCV screening for the different vulnerable populations in community pharmacies could help prevent further undetected HCV infections. This pilot aimed to assess the feasibility and pharmacist acceptance of HCV rapid antibody saliva testing in community pharmacies. Methods A structured pharmaceutical care intervention was developed that included addressing, informing, and screening clients, as well as referral and reporting to subsequent health care providers. Participating pharmacies from French-, German- and Italian-speaking parts of Switzerland were trained to provide this service to local vulnerable populations. Information on client recruitment, feasibility, and acceptability of HCV screening was collected. Results Of 36 pharmacies initially recruited, 25 started the pilot and approached 435 clients, 145 of whom (33%) were interested in screening. Eight of these rapid antibody tests returned positive (prevalence rate: 5.5%). Facilitators were being able to offer a free rapid test (73%), followed by having training prior to the project (67%) and having a new service to offer (67%). The possibility of clients reacting dismissively (53%) and of unsettling clients (47%) were reported to be the main barriers. Conclusions This pilot demonstrated the general feasibility of an HCV screening service with rapid antibody saliva testing in Swiss community pharmacies, which achieved a higher prevalence rate than national estimates. With appropriate communication training and remuneration, Swiss community pharmacies could be an important partner in implementing HCV elimination strategies.https://doi.org/10.1186/s12879-023-08362-1Hepatitis CHCVCommunity Pharmacy ServicesSalivaVulnerable
spellingShingle Dominik Stämpfli
Tamara Leila Imfeld-Isenegger
Kurt E. Hersberger
Markus Messerli
Hepatitis C virus screening in community pharmacies: results on feasibility from a Swiss pilot
BMC Infectious Diseases
Hepatitis C
HCV
Community Pharmacy Services
Saliva
Vulnerable
title Hepatitis C virus screening in community pharmacies: results on feasibility from a Swiss pilot
title_full Hepatitis C virus screening in community pharmacies: results on feasibility from a Swiss pilot
title_fullStr Hepatitis C virus screening in community pharmacies: results on feasibility from a Swiss pilot
title_full_unstemmed Hepatitis C virus screening in community pharmacies: results on feasibility from a Swiss pilot
title_short Hepatitis C virus screening in community pharmacies: results on feasibility from a Swiss pilot
title_sort hepatitis c virus screening in community pharmacies results on feasibility from a swiss pilot
topic Hepatitis C
HCV
Community Pharmacy Services
Saliva
Vulnerable
url https://doi.org/10.1186/s12879-023-08362-1
work_keys_str_mv AT dominikstampfli hepatitiscvirusscreeningincommunitypharmaciesresultsonfeasibilityfromaswisspilot
AT tamaraleilaimfeldisenegger hepatitiscvirusscreeningincommunitypharmaciesresultsonfeasibilityfromaswisspilot
AT kurtehersberger hepatitiscvirusscreeningincommunitypharmaciesresultsonfeasibilityfromaswisspilot
AT markusmesserli hepatitiscvirusscreeningincommunitypharmaciesresultsonfeasibilityfromaswisspilot